Gregory L. Price

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

Sara M. Tolaney, Andrew Wardley, Stefania Zambelli et al. · The Lancet Oncology · 2020 · 261 citations

Medicine, Oncology, Pharmacology +16

Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy

Peter A. Kaufman, Masakazu Toi, Patrick Neven et al. · The Oncologist · 2019 · 83 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Survival Patterns in United States (US) Medicare Enrollees with Non-CML Myeloproliferative Neoplasms (MPN)

Gregory L. Price, Keith L. Davis, Sudeep Karve et al. · PLoS ONE · 2014 · 72 citations · Full text

Medicine, Internal Medicine, Oncology +14

Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer

Matthew P. Goetz, Miguel Martín, Eriko Tokunaga et al. · The Oncologist · 2020 · 55 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia

Srđan Verstovšek, Ruben A. Mesa, Mohamed E. Salama et al. · Leukemia Research · 2017 · 39 citations · Full text

Medicine, Hematology, Pharmacology +12